Halozyme Therapeutics (NASDAQ:HALO) Rating Increased to Buy at Wall Street Zen

Wall Street Zen upgraded shares of Halozyme Therapeutics (NASDAQ:HALO) from a hold rating to a buy rating in a report released on Saturday morning.

Several other equities analysts also recently commented on HALO. HC Wainwright boosted their price target on shares of Halozyme Therapeutics from $90.00 to $95.00 and gave the stock a “buy” rating in a research note on Wednesday, April 29th. Morgan Stanley dropped their price target on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research note on Tuesday, May 12th. Wells Fargo & Company boosted their price target on shares of Halozyme Therapeutics from $65.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 19th. Benchmark boosted their price target on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, February 19th. Finally, TD Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Wednesday, February 18th. Seven research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $80.67.

Halozyme Therapeutics Stock Performance

Shares of HALO stock opened at $67.12 on Friday. The firm has a 50 day moving average of $65.65 and a two-hundred day moving average of $68.64. The stock has a market capitalization of $7.96 billion, a PE ratio of 24.14, a P/E/G ratio of 0.27 and a beta of 0.89. The company has a quick ratio of 3.66, a current ratio of 2.76 and a debt-to-equity ratio of 8.81. Halozyme Therapeutics has a 52 week low of $48.64 and a 52 week high of $82.22.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, topping the consensus estimate of $1.54 by $0.06. The business had revenue of $376.71 million during the quarter, compared to the consensus estimate of $358.60 million. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The company’s quarterly revenue was up 42.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.11 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. On average, research analysts predict that Halozyme Therapeutics will post 7.66 EPS for the current fiscal year.

Insiders Place Their Bets

In other Halozyme Therapeutics news, COO Cortney Caudill sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, March 9th. The shares were sold at an average price of $67.80, for a total transaction of $1,356,000.00. Following the completion of the transaction, the chief operating officer owned 14,366 shares in the company, valued at $974,014.80. The trade was a 58.20% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $64.24, for a total transaction of $1,284,800.00. Following the transaction, the chief executive officer owned 767,780 shares of the company’s stock, valued at $49,322,187.20. This trade represents a 2.54% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 120,482 shares of company stock worth $8,200,842 in the last 90 days. Corporate insiders own 2.50% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in HALO. Root Financial Partners LLC acquired a new position in shares of Halozyme Therapeutics in the 3rd quarter valued at $25,000. Larson Financial Group LLC boosted its holdings in shares of Halozyme Therapeutics by 3,118.2% in the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 343 shares in the last quarter. Measured Wealth Private Client Group LLC boosted its holdings in shares of Halozyme Therapeutics by 51.5% in the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 124 shares in the last quarter. Richardson Financial Services Inc. boosted its holdings in shares of Halozyme Therapeutics by 87.6% in the 3rd quarter. Richardson Financial Services Inc. now owns 424 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 198 shares in the last quarter. Finally, Clearstead Advisors LLC boosted its holdings in shares of Halozyme Therapeutics by 107.7% in the 3rd quarter. Clearstead Advisors LLC now owns 511 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 265 shares in the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.